LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Accueil・Liste d'Actions・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Fermé

Secteur Soins de santé

16.09 -0.62

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

15.97

Max

16.09

Chiffres clés
By Trading Economics
Revenu	17M 33M
Ventes	36M 242M
BPA	0.2
Marge bénéficiaire	13.797
Employés	597
EBITDA	12M 33M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+67.58 upside

Dividendes
By Dow Jones
Prochains Résultats	31 oct. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	119M 2.7B
Ouverture précédente	16.71
Clôture précédente	16.09

Sentiment de l'Actualité

By Acuity

100%

340 / 365 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

15.69 / 16.33 Support & Résistance

ACADIA Pharmaceuticals Inc Graphique

Actualités Associées

6 sept. 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept. 2024, 21:18 UTC

Actualités

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept. 2024, 21:05 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept. 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 sept. 2024, 20:39 UTC

Résultats

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept. 2024, 20:35 UTC

Actualités

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept. 2024, 20:34 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept. 2024, 20:11 UTC

Actualités

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept. 2024, 19:51 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept. 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept. 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept. 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept. 2024, 18:27 UTC

Actualités

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept. 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 sept. 2024, 18:15 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 sept. 2024, 18:12 UTC

Actualités

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 sept. 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 sept. 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 sept. 2024, 17:30 UTC

Actualités

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 sept. 2024, 17:27 UTC

Actualités

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 sept. 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 sept. 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6 sept. 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 sept. 2024, 16:35 UTC

Résultats

Actions en Tendance

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 sept. 2024, 16:33 UTC

Acquisitions, Fusions, Rachats

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 sept. 2024, 16:20 UTC

Market Talk

Résultats

Tech, Media & Telecom Roundup: Market Talk

6 sept. 2024, 16:20 UTC

Résultats

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 sept. 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 sept. 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 sept. 2024, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

Comparaison

Variation de prix

ACADIA Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

67.58% hausse

Prévisions sur 12 Mois

Moyen 26.93 USD 67.58%

Haut 39 USD

Bas 17 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

18 ratings

Achat

Maintien

Vente

Basé sur 18 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

15.69 / 16.33Support & Résistance

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

340 / 365Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

À Propos ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).